- Home
- TBPH vs LX Comparison
TBPH vs LX Comparison
Compare TBPH & LX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- LX
- Stock Information
- Founded
- TBPH 2013
- LX 2013
- Country
- TBPH United States
- LX China
- Employees
- TBPH N/A
- LX N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- LX Finance: Consumer Services
- Sector
- TBPH Health Care
- LX Finance
- Exchange
- TBPH Nasdaq
- LX Nasdaq
- Market Cap
- TBPH 699.0M
- LX 666.3M
- IPO Year
- TBPH N/A
- LX 2017
- Fundamental
- Price
- TBPH $18.81
- LX $3.42
- Analyst Decision
- TBPH Strong Buy
- LX
- Analyst Count
- TBPH 4
- LX 0
- Target Price
- TBPH $24.25
- LX N/A
- AVG Volume (30 Days)
- TBPH 569.5K
- LX 4.3M
- Earning Date
- TBPH 11-10-2025
- LX 11-24-2025
- Dividend Yield
- TBPH N/A
- LX 11.35%
- EPS Growth
- TBPH N/A
- LX 86.38
- EPS
- TBPH 0.58
- LX 1.28
- Revenue
- TBPH $80,327,000.00
- LX $1,956,013,429.00
- Revenue This Year
- TBPH $79.82
- LX $6.40
- Revenue Next Year
- TBPH N/A
- LX $17.75
- P/E Ratio
- TBPH $32.54
- LX $2.95
- Revenue Growth
- TBPH 27.12
- LX 0.80
- 52 Week Low
- TBPH $7.90
- LX $3.33
- 52 Week High
- TBPH $18.96
- LX $11.64
- Technical
- Relative Strength Index (RSI)
- TBPH 68.84
- LX 33.79
- Support Level
- TBPH $17.50
- LX $3.37
- Resistance Level
- TBPH $18.58
- LX $3.88
- Average True Range (ATR)
- TBPH 0.99
- LX 0.22
- MACD
- TBPH 0.16
- LX -0.03
- Stochastic Oscillator
- TBPH 98.49
- LX 7.26
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.